This is a powerful medicine used to treat certain types of cancer, like leukemia. It works by blocking specific proteins (called kinases) that help cancer cells grow and multiply. It's often called Gleevec or Glivec.
Every report comes from a Lived member, sent anonymously.
Have you tried Gleevec (Imatinib) for CML (Chronic Myeloid Leukemia)?
Imatinib, sold under the brand name Gleevec (Glivec in Europe) and as generic tablets, is a targeted cancer medicine taken by mouth. Its best-known use is chronic myeloid leukemia (CML), a blood cancer in which the bone marrow makes too many abnormal white blood cells. It is approved for adults and children with newly diagnosed CML that carries the Philadelphia chromosome, the gene change behind CML, and for more advanced phases of the disease. It is also approved for gastrointestinal stromal tumors (GIST), tumors that grow in the wall of the stomach or intestine. It treats GIST that cannot be removed with surgery or has spread, and it is given after surgery to lower the chance that a removed GIST comes back when the tumor's size, growth rate or location, or a rupture, suggests a meaningful risk of return. Less common approved uses include Philadelphia chromosome-positive acute lymphoblastic leukemia (in adults whose disease has returned or resisted treatment, and alongside chemotherapy in newly diagnosed children), dermatofibrosarcoma protuberans (a rare tumor under the skin) that cannot be fully removed or has returned or spread, and several rare blood disorders, including some forms of hypereosinophilic syndrome (too many eosinophils, a type of white blood cell), aggressive systemic mastocytosis (mast cells, a type of immune cell, building up in organs) and myelodysplastic/myeloproliferative disease (bone marrow disorders that make abnormal blood cells). For some of these, testing for a specific gene change shows whether imatinib is likely to help. Imkeldi is a liquid form of imatinib for people who have trouble with tablets. For CML, imatinib is one of several first-choice options. Newer medicines in the same family, such as dasatinib, nilotinib and bosutinib, are alternatives, and generic imatinib is considered a cost-effective first choice.
Kinases are enzymes that act as on-off switches for cell growth. In CML, genetic material rearranges to form the Philadelphia chromosome, which produces an abnormal kinase called BCR-ABL. Unlike a normal kinase, it is stuck in the on position, driving leukemia cells to keep multiplying. Imatinib blocks BCR-ABL, so the leukemia cells stop growing and many of them die off. Imatinib also blocks two related switches, KIT and the receptor for platelet-derived growth factor (PDGF). Many GIST cells carry an overactive KIT, which is why the same medicine can control a tumor in the stomach or intestine. Because imatinib targets a specific driver, it works best when that driver is present. If the disease does not respond well enough, doctors usually switch to another medicine.
Imatinib is taken by mouth, usually once a day, with a meal and a large glass of water to reduce stomach upset. The dose depends on the condition. For example, 400 mg a day is a common dose for early-phase CML and for GIST, while advanced CML and some other conditions use higher doses, and some rare blood disorders start lower. Doses of 800 mg a day are split into two doses. Children's doses are based on body size. The prescriber may lower the dose for severe liver problems or reduced kidney function, and may raise or lower it later depending on response and side effects. Swallow the tablets whole rather than chewing or crushing them. If swallowing is difficult, the tablets can be stirred into water or apple juice until they break apart, and the mixture should be drunk right away. The Imkeldi liquid must be measured with the oral syringe and bottle adapter from the pharmacy, not a kitchen spoon. If a dose is missed, skip it and take the next dose at the usual time; do not take two doses together. Do not change the dose or stop imatinib without talking to the prescriber.
Most people have some side effects, usually mild to moderate. The most common are swelling (often puffiness around the eyes or in the lower legs), nausea, vomiting, diarrhea, muscle cramps, muscle and bone pain, rash, tiredness and stomach pain. Taking doses with food helps with nausea, and many of these effects can be managed without stopping treatment. Some people feel dizzy or sleepy or have blurred vision, so take care with driving until you know how imatinib affects you. Fluid retention occasionally becomes serious, with fluid collecting around the lungs or heart. Weigh yourself regularly and tell the care team about unexpected rapid weight gain. Call the care team right away for shortness of breath, chest pain, or a fast or irregular heartbeat. Imatinib can also lower blood counts, so fever, chills, sore throat or other signs of infection, and unusual bruising or bleeding (including black or bloody stools) need a prompt call. Liver injury is uncommon but can be severe. Yellowing of the skin or eyes, loss of appetite, or pain in the upper right side of the abdomen needs an immediate call to the care team. So do a peeling or blistering rash, which can signal a severe skin reaction; passing much less urine than usual, a possible sign of kidney problems; and severe abdominal pain or bloating, which can point to bleeding or a tear in the stomach or intestine.
Imatinib is broken down in the liver by an enzyme called CYP3A4, and it also slows that enzyme, so interactions work in both directions. Medicines that speed the enzyme up, such as the antibiotic rifampin, the seizure medicines phenytoin, carbamazepine and phenobarbital, the steroid dexamethasone and the herbal supplement St. John's wort, can lower imatinib levels enough to weaken it. Other medicines, such as the antibiotic clarithromycin and the antifungal ketoconazole, and grapefruit juice can raise imatinib levels; avoid grapefruit while taking it. Imatinib can also raise levels of other medicines, including some sedatives, blood pressure medicines and cholesterol-lowering statins. People who need a blood thinner are usually given a heparin-type medicine instead of warfarin. Tell the prescriber and pharmacist about every medicine and supplement, including iron supplements, and mention imatinib before any surgery or dental work. Imatinib can harm a developing baby. People who could become pregnant should use highly effective birth control during treatment and for 14 days after the last dose, and should tell the doctor promptly about a pregnancy or plans for one. Do not breastfeed during treatment and for one month after the last dose. In children and pre-teens, imatinib can slow growth, so height is tracked closely. People with heart disease, kidney or liver problems need closer monitoring, and people who take thyroid hormone after thyroid removal may need more frequent thyroid tests.
Imatinib is usually a long-term treatment, and the first months involve frequent blood tests: blood counts weekly in the first month, every two weeks in the second month and every few months after that, with liver tests before starting and about monthly. Low blood counts are most likely early on, and the dose may be paused or reduced if they drop. In CML, blood counts usually start to improve within the first few months. Response is then tracked with a sensitive blood test called quantitative polymerase chain reaction (PCR), which measures how much BCR-ABL activity remains in the blood. Results are reported on a standard international scale, where 10% is roughly a tenfold drop from typical levels at diagnosis and later milestones go lower. Doctors compare the result with these milestones; a confirmed level above 10% at 3 months means the treatment is not working well enough and should be changed. Switching to another medicine in the same family is also common when side effects cannot be managed. With this kind of treatment, most people with chronic-phase CML now have a normal life expectancy; in the landmark trial, about 83% of people who started on imatinib were alive 10 years later. Some people with CML who keep a very deep, stable response for several years can try stopping under a specialist's close monitoring. About half need to restart, usually within the first 6 to 8 months, and about 90 to 95% of them regain their earlier response when they do. This is a planned decision with frequent testing, never something to try alone. After surgery for GIST, imatinib is mainly offered when the tumor's size, growth rate, location or a rupture suggest a meaningful chance of return, and 3 years is the usual course for people at high risk, although the ideal length is not known. For GIST that has spread or cannot be removed, it is usually continued for as long as it keeps the disease under control and is tolerated.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Gleevec (Imatinib), what you've noticed, or ask the community a question.